文献速递脑血管病

常规临床实践中血管内取栓联合或不联合阿替普酶后的结局

Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项观察性队列研究纳入美国555家医院在2019年2月1日至2020年6月30日期间因急性缺血性卒中在最后已知良好状态6小时内接受血管内取栓的成人患者,比较接受阿替普酶与未接受阿替普酶患者的8项预设结局;调整协变量后,阿替普酶与更好的院内生存和功能结局相关,但症状性颅内出血风险更高。

要点

  • 接受阿替普酶的患者出院死亡率11.1% vs 未接受者13.9%(aOR 0.83;95%CI 0.77-0.89;P<.001)。
  • 接受阿替普酶的患者出院时改良Rankin量表≤2分比例28.5% vs 20.7%(aOR 1.36;95%CI 1.28-1.45;P<.001)。
  • 接受阿替普酶的患者症状性颅内出血风险6.5% vs 5.3%(OR 1.28;95%CI 1.16-1.42;P<.001)。

核心结论

  • 在因急性缺血性卒中接受血管内取栓的患者中,调整其他协变量后,静脉阿替普酶治疗与更好的院内生存和功能结局相关,但症状性颅内出血风险更高。

研究设计与样本

  • 这是一项观察性队列研究,于2019年2月1日至2020年6月30日开展,纳入美国555家医院Get With The Guidelines-Stroke登记中在最后已知良好状态6小时内接受血管内取栓的成人急性缺血性卒中患者。
  • 排除无出院去向信息和院内卒中患者后,共纳入15832例接受血管内取栓的患者(中位[IQR]年龄72.0[61.0-82.0]岁;7932例女性[50.1%])。

主要发现

  • 10548例(66.7%)接受阿替普酶,5284例(33.4%)未接受。
  • 接受阿替普酶的患者较未接受者更年轻、经急救医疗服务到达更快、房颤/高血压/糖尿病等合并症更少,但美国国立卫生研究院卒中量表(NIHSS)评分相似。
  • 接受阿替普酶的患者出院死亡率11.1%(10548例中1173例)vs 未接受者13.9%(5284例中734例);aOR 0.83;95%CI 0.77-0.89;P<.001。
  • 接受阿替普酶的患者出院时改良Rankin量表≤2分(无重大残疾)比例28.5%(8490例中2415例)vs 未接受者20.7%(4322例中894例);aOR 1.36;95%CI 1.28-1.45;P<.001。
  • 接受阿替普酶的患者改良脑梗死溶栓分级≥2b(再灌注更好)比例90.9%(9318例中8474例)vs 未接受者88.0%(4705例中4140例);aOR 1.39;95%CI 1.28-1.50;P<.001;症状性颅内出血6.5%(10530例中685例)vs 5.3%(5249例中279例);OR 1.28;95%CI 1.16-1.42;P<.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effectiveness and safety of intravenous alteplase given before or concurrently with endovascular thrombectomy (EVT) is uncertain. Randomized clinical trials suggest there is little difference in outcomes but with only modest precision and insufficient power to analyze uncommon outcomes including symptomatic intracranial hemorrhage (sICH). OBJECTIVE: To determine whether 8 prespecified outcomes are different in patients with acute ischemic stroke treated in routine clinical practice with EVT with alteplase compared with patients treated with EVT alone without alteplase. It was hypothesized that alteplase would be associated with higher risk of sICH. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study conducted from February 1, 2019, to June 30, 2020, that included adult patients with acute ischemic stroke treated with EVT within 6 hours of time last known well, after excluding patients without information on discharge destination and patients with in-hospital stroke. Participants were recruited from Get With The Guidelines-Stroke, a large nationwide registry of patients with acute ischemic stroke from 555 hospitals in the US. EXPOSURES: Intravenous alteplase or no alteplase. MAIN OUTCOMES AND MEASURES: Prespecified outcomes were discharge destination, independent ambulation at discharge, modified Rankin score at discharge, discharge mortality, cerebral reperfusion according to modified Thrombolysis in Cerebral Infarction grade, and sICH. RESULTS: There were 15 832 patients treated with EVT (median [IQR] age, 72.0 [61.0-82.0] years; 7932 women [50.1%]); 10 548 (66.7%) received alteplase and 5284 (33.4%) did not. Patients treated with alteplase were younger, arrived via Emergency Medical Services sooner, were less likely to have certain comorbidities, including atrial fibrillation, hypertension, and diabetes, but had similar National Institutes of Health Stroke Severity (NIHSS) scores. Compared with patients who did not receive alteplase treatment, patients treated with alteplase were less likely to die (11.1% [1173 of 10 548 patients] vs 13.9% [734 of 5284 patients]; adjusted odds ratio [aOR] 0.83; 95% CI, 0.77-0.89; P < .001), more likely to have no major disability based on modified Rankin scale of 2 or less at discharge (28.5% [2415 of 8490 patients] vs 20.7% [894 of 4322 patients]; aOR, 1.36; 95% CI, 1.28-1.45; P < .001), and to have better reperfusion based on modified Thrombolysis in Cerebral Infarction grade 2b or greater (90.9% [8474 of 9318 patients] vs 88.0% [4140 of 4705 patients]; aOR, 1.39; 95% CI, 1.28-1.50; P < .001). However, alteplase treatment was associated with higher risk of sICH (6.5% [685 of 10 530 patients] vs 5.3% [279 of 5249 patients]; OR, 1.28; 95% CI, 1.16-1.42; P < .001). CONCLUSIONS AND RELEVANCE: In this observational cohort study of patients treated with EVT, intravenous alteplase treatment was associated with better in-hospital survival and functional outcomes but higher sICH risk after adjusting for other covariates.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Smith EE, Zerna C, Solomon N, et al. Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice. JAMA Neurol. 2022. PMID: 35696198. doi:10.1001/jamaneurol.2022.1413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。